StockNews.com assumed coverage on shares of Pulmatrix (NASDAQ:PULM – Free Report) in a report released on Thursday. The firm issued a hold rating on the biotechnology company’s stock.
Pulmatrix Trading Down 1.0 %
Shares of PULM opened at $1.93 on Thursday. The stock has a market capitalization of $7.05 million, a P/E ratio of -0.80 and a beta of 0.94. The firm’s fifty day simple moving average is $1.92 and its two-hundred day simple moving average is $1.89. Pulmatrix has a 12 month low of $1.55 and a 12 month high of $2.84.
Pulmatrix (NASDAQ:PULM – Get Free Report) last released its quarterly earnings data on Friday, May 10th. The biotechnology company reported $0.23 earnings per share (EPS) for the quarter. The company had revenue of $5.89 million for the quarter. Pulmatrix had a negative net margin of 75.73% and a negative return on equity of 44.05%.
Pulmatrix Company Profile
Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.
Recommended Stories
- Five stocks we like better than Pulmatrix
- How to Calculate Retirement Income: MarketBeat’s Calculator
- Upwork Stock’s Outlook: Numbers Solid Despite Gen-AI Challenges
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- What’s Behind Walgreens Stock Plunge: What Investors Can Do Next
- 3 Best Fintech Stocks for a Portfolio Boost
- MarketBeat Week in Review – 6/24 – 6/28
Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with MarketBeat.com's FREE daily email newsletter.
